Purpose: In this analysis, we compared costs and explored the cost-effectiveness of subsequent-line treatment with cetuximab or panitumumab in patients with wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) after previous chemotherapy treatment failure. Data were used from ASPECCT (A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer), a Phase III, head-to-head randomized noninferiority study comparing the efficacy and safety of panitumumab and cetuximab in this population.
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer in both men and women in the United States and the second leading cause of cancer death. 1 In 2015, it was estimated that there would be 132,700 new cases of colon and rectum cancer and an estimated 49,700 people would die of this disease. Approximately 20% have metastatic CRC (mCRC) at diagnosis, and metastases eventually develop in 50% to 60% of all patients. [1] [2] [3] Patients with mCRC experience significant morbidity and diminished quality of life. The 5-year relative survival rate is o13% in patients with mCRC, indicating a continued need to improve treatment outcomes. 1 Surgical resection of metastases is curative in a very small proportion of patients; therefore, the goal of treatment for most patients with mCRC is to prolong survival while maintaining quality of life.
Chemotherapy is the first treatment option for metastatic disease when tumor lesions are not fully resectable. Regimens consisting of fluoropyrimidine and oxaliplatin (ie, FOLFOX) or irinotecan (ie, FOLFIRI) can be considered standard options for first-line treatment of mCRC. In randomized trials in which patients received either FOLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI, median progression-free survival (PFS) ranged from 7 months to 8.5 months. 4, 5 In addition to various chemotherapeutic regimens, current treatments for mCRC include targeted monoclonal antibodies directed against the epidermal growth factor receptor (EGFR), such as panitumumab and cetuximab, and bevacizumab, a humanized monoclonal antibody that binds the vascular endothelial growth factor. Trials comparing the use of these types of targeted therapies in patients with mCRC have demonstrated a significant increase in survival. [6] [7] [8] [9] [10] [11] [12] Patients with RAS gene mutations should not be treated with an anti-EGFR agent because these mutations are predictive of a lack of response to panitumumab and cetuximab. 2, 3 Approximately 50% of patients with mCRC have tumors exhibiting RAS mutations, 13 including 40% with KRAS (exon 2) mutations.
14 Therefore, 50% to 60% of patients with mCRC would be eligible for treatment with panitumumab and cetuximab. Identifying KRAS status and ultimately RAS status through genotyping may reduce treatment costs by allowing physicians to target patients who are likely to benefit from treatment with EGFR inhibitors and to minimize the number of patients receiving anti-EGFR agents who are unlikely to respond favorably.
Several clinical trials have been conducted to study targeted therapies in the treatment of mCRC. The ASPECCT (A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer) clinical trial was designed to evaluate the efficacy and safety of treatment with panitumumab (n ¼ 499) versus cetuximab (n ¼ 500) in patients with previously treated, chemotherapy-resistant, wild-type KRAS (exon 2) mCRC. This therapy resulted in an estimated median PFS of 4.1 months (95% CI, 3.2-4.8) in the panitumumab arm and 4.4 months (95% CI, 3.2-4.8) in the cetuximab arm. The estimated median overall survival (OS) was 10.4 months (95% CI, 9.4-11.6) in the panitumumab arm and 10.0 months (95% CI, 9.3-11.0) in the cetuximab arm. 15 These 17 The value framework will consider a particular treatment regimen's effectiveness, the severity of the expected side effects, and the treatment's costs to evaluate the relative value of the treatments that are available and to determine the best treatment approach. To this point, economic modeling of noninferior trial results can assist with estimation of treatment costs (drug acquisition and administration) as well as the costs of side effects or toxicities between 2 treatments.
Published cost-effectiveness studies evaluating subsequent-line treatment with cetuximab or panitumumab in patients with wild-type KRAS (exon 2) mCRC have only examined the cost-effectiveness of these anti-EGFR therapies relative to best supportive care (BSC). [18] [19] [20] To our knowledge, an economic model that directly compares panitumumab versus cetuximab in the treatment of patients with mCRC after prior chemotherapy treatment failure has not yet been published.
Given the noninferior efficacy results demonstrated in the ASPECCT study, we developed a decisionanalytic model to perform a cost-minimization analysis, assuming equivalent efficacy (PFS), between panitumumab (intravenous infusion, 6 mg/kg every 2 weeks until disease progression) and cetuximab (intravenous infusion, loading dose of 400 mg/m 2 and weekly maintenance doses of 250 mg/m 2 until disease progression) monotherapy in chemorefractory patients with wild-type KRAS (exon 2) mCRC. Data from the head-to-head ASPECCT trial were used.
To examine the benefit suggested by Briggs and O'Brien 16 of probabilistic cost-effectiveness modeling using noninferiority trial results, we also developed a semi-Markov model to evaluate the cost-effectiveness of panitumumab monotherapy versus cetuximab monotherapy in chemotherapy-resistant patients with wild-type KRAS (exon 2) mCRC using the full information (uncertainty) from the ASPECCT trial. Both analyses were conducted from a US third-party payer perspective.
MATERIALS AND METHODS Population
The model population in both models was based on the patient population included in the head-to-head ASPECCT clinical trial comparing panitumumab and cetuximab in the treatment of mCRC. Briefly, this population was defined as adults (age Z18 years) with wild-type KRAS (exon 2) with a diagnosis of mCRC for whom previous treatment with regimens containing irinotecan and oxaliplatin had failed and for whom at least 1 thymidylate synthase inhibitor had been received. In addition, enrolled patients had an Eastern Cooperative Oncology Group status of 0, 1, or 2 and adequate hematologic, renal, hepatic, and metabolic function.
Model Structure
The cost-minimization analysis assumed panitumumab and cetuximab had equivalent PFS and estimated the costs associated with drug acquisition, treatment administration frequency (biweekly for panitumumab, weekly for cetuximab), and incidence of infusion reactions. Costs were estimated over the time horizon of the model, which was determined according to the length of therapy as reflected by the average PFS. The cost-minimization model structure is illustrated in Figure 1 .
The cost-effectiveness analysis took the form of a probabilistic semi-Markov model, allowing patients to transition to various health states over time (Figure 2) . In the cost-effectiveness analysis, the model begins with a cohort of patients initiating subsequent mCRC treatment after discontinuing failed chemotherapy after progression. Patients cycle through the model every 2 weeks. During each cycle, patients may transition to different mutually exclusive health states or stay in the same health state based on health state transition probabilities; each health state has a corresponding cost and outcome. For the base-case time horizon, Markov cycles are repeated for the lifetime of a patient. The semi-Markov model concludes when the entire patient cohort has died. Total costs and outcomes are calculated by summing across cycles.
Inputs

Transition Probabilities
In clinical trials of oncology products, KaplanMeier plots for PFS and OS are often right-censored because data collection ends before all patients experience disease progression and/or death. Because of the right censoring of the curves, parametric survival curves can be fit to patient-level survival data to extrapolate beyond the data collection period.
In the cost-minimization analysis, data from the ASPECCT clinical trial were used to conduct parametric survival analyses on the PFS of wild-type KRAS (exon 2) patients treated with panitumumab. The parametric survival modeling was coded in SAS version 9.3 (SAS Institute, Inc, Cary, North Carolina) by using the LIFEREG procedure. Three parametric models were tested, based on the intrinsic assumptions they make regarding changes to the hazard rate over time. The models were exponential, Weibull, and loglogistic. Based on graphical overlay of the curves and the Kaplan-Meier plot, goodness-of-fit statistics
(Akaike information criterion), and face validity of long-term survival projections (as suggested by Latimer 21 ), the best-fit survival curve for panitumumab was the Weibull, which was selected as the basecase estimate of mean PFS for panitumumab as well as cetuximab given that the model assumed both treatments had the same efficacy.
In the cost-effectiveness analysis, transition probabilities to disease progression and death for panitumumab and cetuximab were based on parametric survival curves estimated in a patient-level analysis of PFS and OS from the ASPECCT clinical trial. In contrast to the cost-minimization analysis, separate parametric survival curves were estimated for panitumumab and cetuximab by including a covariate for panitumumab treatment in the regression equations; this approach accounted for noninferior ASPECCT trial results (OS HR, 0.97) and the difference in efficacy between panitumumab and cetuximab. Using the same criteria as the cost-minimization analysis, the 
No. of infusions
No. of infusions Unit costs
(drug acquisition and administration)
Adverse event incidence
Cost of treating adverse event Total costs Figure 1 . Cost-minimization model structure.
Clinical Therapeutics
Weibull was selected as the best-fit curve for panitumumab and cetuximab for both PFS and OS in the cost-effectiveness model ( Figures 3 and 4) .
Costs
Aside from the efficacy input parameters, sources were consistent for the input parameters used in both models. Drug acquisition costs in the base-case analysis were modeled by using Medicare average sales prices from the payment allowance limits for Medicare Part B drugs. 22 Wholesale acquisition costs from Red Book 23 were examined in scenario analyses.
Product exposure, defined as the average dose delivered, percentage of doses administered, and therapy duration (for subsequent therapy), were calculated from data in the ASPECCT clinical trial for direct treatment comparators. Premedication, drug acquisition and administration costs, dosing, duration, and other regimen-specific inputs are presented in Table I , along with sources and assumptions. Adverse event treatment incidence and cost inputs are presented in Table II , and non-regimen-specific inputs and costs considered by the models (ie, KRAS mutation testing, physician visits, diagnostic tests, BSC, end-of-life care) are presented in Table III . All costs were inflated to 2014 US dollars by using the medical component of the Consumer Price Index. 24 
Utility Weights
Utility weights, used only in the cost-effectiveness model, were based on EuroQol-5 Dimension questionnaire responses of patients with wild-type KRAS (exon 2) mCRC from the ASPECCT clinical trial during the progression-free period (average of screening and treatment visits during the progression-free period) and during the disease progression period (safety follow-up visit responses). Utility weights were estimated from the questionnaire responses by using the algorithm of Shaw et al 25 for US patients (Table III) .
Outcomes Modeled
The model outcomes calculated for each treatment regimen in the cost-minimization analysis included the cost per treated patient, the cost per 100 treated patients, the cost savings per treated patient, and the cost savings per 100 treated patients receiving panitumumab monotherapy relative to cetuximab monotherapy. The model outcomes calculated for each treatment regimen in the cost-effectiveness analysis included patient survival life-years, quality-adjusted life-years (QALYs), and costs for health care resources. The incremental costs and total life-years and QALYs were calculated to obtain an incremental cost per life-year gained and per QALY gained. All costs and outcomes (benefits) in the model were discounted by using the suggested discount rate in the United States of 3.0% per annum. 26 In the cost-effectiveness analysis, the robustness of the model methods, assumptions, and specific parameters were tested by examining the effect of using alternative methods and data sources for the model inputs in a series of focused scenario analyses conducted around the assumptions and methods used to calculate drug acquisition costs and subsequent treatment. We also examined the effect of changing parameters individually as part of 1-way sensitivity analyses. In addition to 1-way sensitivity analyses, a probabilistic sensitivity analysis was performed to examine the effects of joint uncertainty across all the parameters of the model.
RESULTS
Deterministic Results
The results of the cost-minimization analysis (Table IV) revealed lower projected drug acquisition, administration, and adverse event costs for patients with wild-type KRAS (exon 2) mCRC who received panitumumab versus cetuximab. The projected total cost savings was $9468 (16.5%) per patient treated with panitumumab.
Results from the cost-effectiveness model (Table V) demonstrated slightly better outcomes for patients with wild-type KRAS (exon 2) mCRC who received panitumumab versus cetuximab. The model projected 1.072 life-years for panitumumab and 1.051 life-years for cetuximab. Adjusting for quality of life, panitumumab was estimated to produce 0.736 QALY, whereas cetuximab was estimated to produce 0.726 Clinical Therapeutics Panitumumab is administered over 60 minutes 27, 28 Cetuximab loading dose is administered over 120 minutes and maintenance doses over 60 minutes 28, 29 Average QALY. BSC costs contributed the greatest proportion of total costs modeled (46.0% for panitumumab; 43.5% for cetuximab), followed by monoclonal antibody drug acquisition costs (33.4% for panitumumab; 35.9% for cetuximab). Total drug costs for panitumumab were lower than total drug costs for cetuximab ($50,360 vs $56,377). Costs for administration, adverse events, and end-of-life care were also slightly lower for panitumumab than for cetuximab. However, costs for physician visits, monitoring for disease progression, and BSC were slightly higher for panitumumab than for cetuximab due to longer projected survival. The incremental cost per life-year gained and the incremental cost per QALY gained indicate that with both end points, panitumumab dominated cetuximab (ie, panitumumab was less costly and had * Scheduled physician visits did not include visits for grade 3/4 toxicity treatment or management that occurred on days other than the day of treatment administration. Also, costs of scheduled physician visits during BSC after disease progression were captured as part of the BSC costs and were not included in these cost estimates because the frequency of office visits was likely to be different.
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slightly better outcomes than cetuximab). The results from the cost-effectiveness analysis are consistent with the ASPECCT primary analysis (HR, 0.97) showing noninferiority of panitumumab relative to cetuximab and slightly favoring panitumumab.
Sensitivity Analyses
The 1-way sensitivity analysis from the costeffectiveness model indicated that model outcomes were most sensitive to changes to the Weibull OS treatment coefficient, panitumumab drug costs, BSC costs, and end-of-life costs. Scenario analyses conducted around major model assumptions indicated that the model was robust to alternative assumptions of PFS and OS distributions, wastage, drug acquisition costs, postprogression costs, and the progression-free utility weight method used ( Table VI) .
The probabilistic sensitivity analysis from the costeffectiveness model was conducted by using the observed uncertainty measures of the PFS, OS, and other model inputs. Cost-effectiveness acceptability curves were calculated from 10,000 iterations by using the net monetary benefit statistic across a range of willingness-to-pay thresholds. The cost-effectiveness scatter plot ( Figure 5 ) and acceptability curves ( Figure 6 ) indicate that 92.5% of simulations were below a willingness-to-pay threshold of $50,000 and 98.5% of simulations were below a willingness-to-pay threshold of $100,000. In addition, 45.8% of simulations revealed panitumumab to be less costly, with minimally better outcomes, than cetuximab.
DISCUSSION Results Summary
Cetuximab or panitumumab monotherapy constitutes a standard-of-care treatment in the management of mCRC with wild-type RAS tumors. [1] [2] [3] The AS-PECCT clinical trial met its primary end point, reporting similar OS for both panitumumab and cetuximab (HR, 0.97 [95% CI, 0.84-1.11]) in the treatment of patients with chemorefractory wild-type KRAS (exon 2) mCRC. The cost-minimization model analysis conservatively used the panitumumab treatment effect (PFS HR) of 1.0 from ASPECCT. Deterministic results from the cost-minimization analysis projected panitumumab to be cost-saving relative to cetuximab ($47,876 vs $57,344) per patient. In a separate model, a cost-effectiveness analysis was 
Limitations
The strength of our models reside in the use of data from a well-conducted randomized Phase III head-tohead clinical trial in a homogeneous patient population. Considerable scrutiny was placed on toxicity collection in this study, allowing for a more accurate modeling of cost of toxicities amongst arms. However, as with any model, there were several limitations to the analysis and modeling. Both models assumed dose modifications and dose interruptions in clinical practice that mimic the ASPECCT clinical trial recommendations. This scenario may not be necessarily true in actual clinical practice. For example, many physicians may carry through treatment with chronic aggressive intravenous magnesium supplementation in a setting in which no other treatment options may be available. In addition, the management of skin toxicity in clinical practice may vary from the ASPECCT clinical trial, with variations in the rate of dose interruptions or modifications and/or the implementation of dermatology or podiatry consults. Furthermore, the intensity of skin toxicity within a particular grade of toxicity can vary from 1 patient to another and may not be reflected adequately by the toxicity grading of the National Cancer Institute and Common Terminology Figure 5 . Probabilistic sensitivity analysis (PSA) cost-effectiveness scatter plot. *Quadrant 3 includes iterations in which cetuximab is more effective and more costly than panitumumab. Thus, the incremental cost-effectiveness ratio is switched and is interpreted as cetuximab compared with panitumumab. Iterations greater than the willingness-to-pay (WTP) threshold indicate situations in which panitumumab would be selected over cetuximab, given cetuximab is not cost-effective at the specified WTP threshold. Q1 ¼ more costly, more effective; Q2 ¼ more costly, less effective; Q3 ¼ less costly, less effective; Q4 ¼ less costly, more effective; QALY ¼ quality-adjusted life-year. Criteria for Adverse Events. Despite these limitations, the 1-way sensitivity analysis in the costeffectiveness model indicated relatively minimal impact of panitumumab-related hypomagnesemia or grades 3 and 4 cetuximab infusion reactions on the costeffectiveness results.
In addition, all models are abstractions from real clinical practice and do not take into account all costs and attributes of patient care. However, we have modeled costs that comprise the majority of total costs and those that are likely different between the 2 treatments (eg, drug, administration, adverse events).
Several assumptions were taken into account in the cost-modeling of an infusion reaction. Although most of the clinical sites in the ASPECCT trial were outside the United States, the rate of infusion reactions in the ASPECCT patient population was assumed to be similar for the US patient population. However, it is well known that geographic variations exist in terms of cetuximab infusion reactions. [34] [35] [36] [37] [38] Therefore, the cost-savings and cost-effectiveness of panitumumab may vary across the United States, with likely higher cost savings and better cost-effectiveness outcomes with panitumumab than cetuximab in certain US regions.
CONCLUSIONS
These economic analyses comparing panitumumab and cetuximab in patients with wild-type KRAS (exon 2) mCRC suggest benefits in favor of panitumumab, with cost-savings of almost $9500 per patient in the cost-minimization model, and an incremental cost per QALY gained demonstrating panitumumab to be less costly with marginally better outcomes than cetuximab in the cost-effectiveness model. Such cost-savings can add up, considering that 440,000 new patients are treated for mCRC every year, 40% to 50% of whom are eligible for anti-EGFR therapy. In addition to the potential economic advantage of panitumumab in this setting, panitumumab offers the convenience of biweekly administration over the weekly cetuximab administration, significantly reducing interruptions in patient and caretaker schedules. Furthermore, panitumumab has distinct advantages in terms of hypersensitivity reactions, which can be life-threatening in $ 2% of patients receiving cetuximab but are rarely seen with panitumumab. The advantages of panitumumab in terms of hypersensitivity, scheduling, and costs make it an attractive choice over cetuximab in patients with chemotherapy-refractory CRC. Because the model was based on a monotherapy study in chemotherapy-resistant CRC, questions may remain regarding its applicability to irinotecan þ anti-EGFR therapy in refractory CRC. The majority of patients in the United States receive cetuximab þ irinotecan or panitumumab þ irinotecan in latetreatment settings, rather than anti-EGFR monotherapy. Although a direct comparison of the costs of treatment with panitumumab and cetuximab has not been performed in such settings, there is little evidence to point to a discrepancy in interaction between these 2 monoclonal antibodies and variable chemotherapy backbones. Therefore, we believe that these results could be generalizable to anti-EGFR antibody þ chemotherapy combinations; however, further analysis (particularly in first-line therapy) may be useful.
